These reprogrammed cells upregulated activation markers (CD14, CD117) and downregulated suppressive molecules (PD-L1, CD206), driven by a TME rich in GM-CSF, IL-3, and MIP-1α/β, which enabled them to perform bystander killing of antigen-loss tumor variants. The gene discussed is CD274; the disease is neoplasm.